查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
未分化多形性肉瘤治療的全球市場-2022-2029
市場調查報告書
商品編碼
1129248

未分化多形性肉瘤治療的全球市場-2022-2029

Global Undifferentiated Pleomorphic Sarcoma Therapeutics Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

越來越多的針對未分化多形性肉瘤的臨床試驗預計將推動市場增長。

2020 年 7 月 21 日，Tracon Pharmaceuticals Inc. 宣布宣布接受 1 或 2 線化療後出現進展的局部晚期、不可切除或轉移性未分化多形性肉瘤 (UPS)/肌纖維肉瘤 (MFS)，這是一個關鍵隊列評估 emvaforimab 單獨或與 ipilimumab 聯合用於患有以下疾病的患者的研究這項研究處於第 2 階段。此外，美國國家癌症研究所 (NCI) 和 M.D. 安德森癌症中心在一項 2 期試驗中，研究了已轉移到身體其他部位、局部擴散到附近組織和淋巴結的間變性多形性肉瘤。 sintilimab 用於復發性肉瘤、復發（recurrence）和無法手術切除（不可切除）的患者。 Sintilimab 是一種用於免疫療法的單克隆抗體，有望幫助人體免疫系統對抗疾病並防止腫瘤細胞生長或擴散。因此，從上述陳述來看，預計市場將在預測期內受到驅動。

限制

藥物副作用、缺乏疾病意識、有限的醫療機構要求以及政府對藥物批准的嚴格規定是在預測期內阻礙市場的因素。

行業分析

未分化多形性肉瘤治療市場基於供應鏈分析、報銷方案、定價分析和管道分析等各種行業因素對市場進行了深入分析。

COVID-19 影響分析

COVID-19 大流行正在影響癌症治療的方方面面。結果，出現了治療延誤和失訪的情況。在受大流行影響地區的研究表明，未分化多形性肉瘤的手術減少了。由於在診斷和手術過程中缺乏對患者的考慮，輔助治療被推遲。這對侵襲性惡性腫瘤的預後產生不利影響，導致腫瘤晚期和預後不良。

此外，實驗室已關閉，臨床試驗推遲。相比之下，虛擬癌症多學科團隊會議技術討論了個人治療計劃和後勤支持。放療被考慮用於高危、快速生長的腫瘤患者，大分割有望縮短治療時間。它還有助於更好地分配資源和縮短治療療程。此外，大流行將破壞供應鍊和流程。許多公司將轉移到其他地區以確保產品可用性並保護其供應鏈。因此，從上面這句話來看，市場受到了影響，預計隨著經濟活動的恢復，市場將迅速獲得牽引力。

全球未分化多形性肉瘤治療市場報告將提供對大約 45 多個市場數據表、40 多個數字和 180 頁的訪問。

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

  • 市場影響因子
    • 驅動程序
      • 預計針對未分化多形性肉瘤的臨床試驗的增加將推動市場增長。
    • 限制因素
      • 預計藥物副作用會阻礙市場增長。
    • 機會
    • 影響分析

第五章行業分析

  • 供應鏈分析
  • 定價分析
  • 未滿足的需求分析
  • 管道分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章診斷領域

  • 核磁共振
  • CT 掃描
  • 活檢
  • 健康檢查
  • 其他

第 8 章按治療類型

  • 放射治療
    • 外照射
    • 術中放療 (IORT)
    • 其他
  • 化療
  • 靶向藥物治療
  • 免疫療法
  • 其他

Chapter 9. 按銷售額劃分的藥品銷售額

  • 醫院藥房
  • 零售藥房
  • 在線藥店
  • 醫院
  • 診斷中心
  • 其他

第 10 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 11 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 產品基準
  • 值得關注的重點公司列表

第 12 章公司簡介

  • Pfizer Inc.
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Eisai Inc.
  • AdvaCare Pharma
  • Teva Pharmaceuticals USA, Inc.
  • Bristol-Myers Squibb Company
  • Hikma Pharmaceuticals PLC
  • PV Pharma

第 13 章全球未分化多形性肉瘤治療市場-DataM

簡介目錄
Product Code: DMPH5807

Market Overview

The Undifferentiated Pleomorphic Sarcoma Therapeutics Market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Soft tissue cancers include malignant fibrous histiocytoma, often undifferentiated pleomorphic sarcoma. It's rare cancer that frequently metastasizes to other body regions and returns after treatment. Surgery to remove the cancer cells is typically the first step in treating undifferentiated pleomorphic sarcoma. The use of medications (systemic therapies), such as chemotherapy, targeted therapy, and immunotherapy, is another possibility (most of the drugs are in clinical trials).

Market Dynamics

Increasing clinical trials for undifferentiated pleomorphic sarcoma is expected to drive market growth.

On July 21, 2020, Tracon Pharmaceuticals Inc. conducted a pivotal cohort study evaluating the use of envafolimab alone or in combination with ipilimumab for the treatment of patients with locally advanced, unresectable, or metastatic undifferentiated pleomorphic sarcoma (UPS)/myxofibrosarcoma (MFS) who have progressed on one or two lines of chemotherapy. The research is in Phase 2. Moreover, In a phase II trial, the National Cancer Institute (NCI) and M.D. Anderson Cancer Center examined the effects of sintilimab in treating patients with undifferentiated pleomorphic sarcoma that has metastasized to other parts of the body, spread locally to nearby tissue or lymph nodes, returned (recurrent), or cannot be surgically removed (unresectable). Sintilimab, a monoclonal antibody used in immunotherapy, may aid the body's immune system combat the disease and prevent tumor cells from proliferating and spreading. Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint:

Side effects of the drugs, lack of awareness about the disorder, limited availability of required healthcare facilities and strict government restrictions on drug approval are some factors the market is expected to get hampered in the forecast period.

Industry Analysis

The undifferentiated pleomorphic sarcoma therapeutics market provides in-depth analysis of the market based on various industry factors such as supply chain analysis, reimbursement scenario, pricing analysis, pipeline analysis etc.

COVID-19 Impact Analysis

The COVID-19 pandemic has affected every aspect of cancer care. As a result, there is a delay in treatment or loss of follow-up. Studies from pandemic-affected areas show diminution in undifferentiated pleomorphic sarcoma surgeries. There was a lack of patient care in diagnostic and surgical procedures and a delay in adjuvant therapy. This adversely affects the prognosis of aggressive malignancies and has resulted in upstaging of the tumour and poor prognosis.

Moreover, research laboratories have been shut down, resulting in delays in clinical trials. In contrast, virtual multidisciplinary cancer team meeting technology discussed individual treatment plans and logistics. Patients with high-risk rapidly proliferating tumors were considered for radiotherapy, and shortening treatment duration by hypofractionation has shown promising results. They also help in better allocation of resources and shorten the treatment course. Additionally, the pandemic interrupts the supply chain and process. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of economic activities.

Segment Analysis

Radiation therapy segment is expected to hold the largest market share in undifferentiated pleomorphic sarcoma therapeutics market

The radiation therapy segment is expected to dominate in 2021. The segment is benefited because, in the multimodal treatment of soft tissue sarcomas, radiotherapy (RT) is becoming more important. Intensity-modulated, image-guided, and stereotactic radiation are a few technological advancements that have greatly boosted radiotherapy's potential during the past 20 years and improved patient care. They have permitted either dose escalation (with improved efficacy) or toxicity reduction (with the consequent improved functional outcome). Moreover, healthcare providers usually recommend radiation therapy. This powerful combination allows the best chance of preventing the sarcoma from returning to the same area. For instance, external beam radiation is a type of radiation that comes from a machine that moves around you as you lie on a table. The device targets specific areas of the body with radiation. A sarcoma may be shrunk with radiation before surgery to facilitate removal. It can also be used to eliminate cancer cells following surgery. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global undifferentiated pleomorphic sarcoma therapeutics market

In 2021, North America accounted for the highest revenue share. The rising geriatric population, increasing clinical trials, advancement in the diagnosis of sarcoma, and adoption of new imaging guidelines in the region are some factors the market is expected to boost in the forecast period. For instance, according to the Population Reference Bureau, the number of Americans 65 and older will nearly double from 52 million in 2018 to 95 million by 2060, increasing their percentage of the overall population from 16 percent to 23 percent. There is a diversity gap across generations despite the older adult population being more diverse. The racial/ethnic makeup of the population under 18 is changing more quickly than the group over 65.

Moreover, the following imaging suggestions are part of the clinical practice guidelines provided by the National Comprehensive Cancer Network (NCCN) for STS of the extremities, superficial trunk, head, and neck. All lesions with a decent cancer risk should have sufficient primary tumor imaging. Imaging examinations should include cross-sectional magnetic resonance imaging (MRI) with and without contrast to understand better the size and proximity of nearby visceral tissues and neurovascular landmarks. There may be a need for additional computed tomography (CT) scanning with contrast. Thus, from the above statements, the North American region is expected to hold the largest market share in the forecast period.

Competitive Landscape

Major key players in the undifferentiated pleomorphic sarcoma therapeutics market are Pfizer Inc., Eisai Inc., AdvaCare Pharma, Teva Pharmaceuticals USA, Inc., Bristol-Myers Squibb Company, Hikma Pharmaceuticals PLC, PV Pharma.

Pfizer Inc.:

Overview:

Pfizer Inc. is an American multinational pharmaceutical company that offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. It has a portfolio of over 150 products across 15 therapeutic areas. The company develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology.

Product Portfolio:

DOXORUBICIN HYDROCHLORIDE: Doxorubicin (DOX) is often first-line treatment of undifferentiated/unclassified soft tissue sarcoma (USTS).

The global undifferentiated pleomorphic sarcoma therapeutics market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing clinical trials for undifferentiated pleomorphic sarcoma is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. Side effects of the drugs are expected to hamper the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Supply Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Unmet Needs
  • 5.4. Pipeline Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Diagnosis

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 7.1.2. Market Attractiveness Index, By Diagnosis Segment
  • 7.2. MRI*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. CT scan
  • 7.4. Biopsy
  • 7.5. Physical exam
  • 7.6. Others

8. By Treatment Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.1.2. Market Attractiveness Index, By Treatment Type Segment
  • 8.2. Radiation therapy*
    • 8.2.1. External beam radiation
    • 8.2.2. Intraoperative radiation therapy (IORT)
    • 8.2.3. Others
    • 8.2.4. Introduction
    • 8.2.5. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Chemotherapy
  • 8.4. Targeted drug therapy
  • 8.5. Immunotherapy
  • 8.6. Others

9. By Treatment Sales

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales
    • 9.1.2. Market Attractiveness Index, By Treatment Sales Segment
  • 9.2. Hospital Pharmacies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Retail Pharmacies
  • 9.4. Online Pharmacies
  • 9.5. Hospitals
  • 9.6. Diagnostic Centers
  • 9.7. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Sales

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1. Pfizer Inc.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Eisai Inc.
  • 12.3. AdvaCare Pharma
  • 12.4. Teva Pharmaceuticals USA, Inc.
  • 12.5. Bristol-Myers Squibb Company
  • 12.6. Hikma Pharmaceuticals PLC
  • 12.7. PV Pharma

LIST NOT EXHAUSTIVE

13. Global Undifferentiated Pleomorphic Sarcoma Therapeutics Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Applications
  • 13.3. Contact Us